The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway
6 affiliations
- 1Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
- 2Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
- 3Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
- 4Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
- 5Department of Neurology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
- 6Yantai Municipal Key Medical and Health Laboratory of Yantai Yuhuangding Hospital (Interdisciplinary Brain Science and Geriatric Health Laboratory), Qingdao University, Yantai, China
Abstract
Background: Although papillary thyroid carcinoma (PTC) has a relatively good prognosis, it is also prone to recurrence and metastasis. Cyclin-dependent kinase inhibitor 2 A (CDKN2A) can affect tumor progression by regulating ferroptosis, but its role in PTC remains unclear.
Materials and methods: The expression of CDKN2A, p14, p16, GPX4, and TFRC in PTC was assessed by qPCR, western blotting, and immunohistochemistry, and their clinical correlations were analyzed. In TPC-1 and BCPAP cells, CDKN2A/p14/p16 expression was modulated, followed by evaluation of ferroptosis-related changes using GPX4, TFRC, Fe2⁺, ROS, GSH, C11-BODIPY lipid peroxidation, and transmission electron microscopy. Cell proliferation and migration were assessed by CCK-8, colony formation, wound-healing, and Transwell assays. The p53/SLC7A11/GPX4 pathway was examined, and rescue experiments were conducted using p53 agonist and inhibitor. In vivo tumorigenicity was evaluated using a nude mouse xenograft model.
Results: CDKN2A was upregulated in PTC and associated with advanced clinicopathological features and lipid metabolism, but was not an independent prognostic factor. Silencing CDKN2A (p14, p16) induced ferroptosis, inhibiting tumor progression; in contrast, overexpression of p14 and p16 inhibited ferroptosis and promoted malignant phenotypes, with p16 playing a predominant role. Moreover, overexpression of p16 could partially resist the induction of ferroptosis by RSL3. Mechanistically, p53 agonist/inhibitor rescue experiments suggested p16 affected p53/SLC7A11/GPX4 pathway. In vivo, p16 overexpression increased tumor growth by inhibiting ferroptosis.
Conclusion: CDKN2A promotes PTC progression by suppressing ferroptosis via indirect regulation of p53/SLC7A11/GPX4 pathway, primarily through the p16 isoform. Targeted inhibition of p16 isoform is a potential therapeutic strategy for PTC.
Related
- Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
- ECM stiffness inhibits ferroptosis to promote HCC progression via the FOXA1-CDON-HMGB1/p53 pathway.
- CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
- Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms
- Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression
BibTeX
@article{wang2026isoform,
title = {{The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway}},
author = {Yao Wang and Ya-Kui Mou and Ting Yang and Han-Rui Wang and Xiao-Yu Song and Wan-Chen Liu and Hui Shen and Chao Ren and Xi-Cheng Song},
journal = {Cancer Biology \& Therapy},
year = {2026},
month = nov,
doi = {10.1080/15384047.2026.2760033},
url = {https://doi.org/10.1080/15384047.2026.2760033},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway
AU - Yao Wang
AU - Ya-Kui Mou
AU - Ting Yang
AU - Han-Rui Wang
AU - Xiao-Yu Song
AU - Wan-Chen Liu
AU - Hui Shen
AU - Chao Ren
AU - Xi-Cheng Song
PY - 2026
DA - 2026/11/11
JO - Cancer Biology & Therapy
DO - 10.1080/15384047.2026.2760033
UR - https://doi.org/10.1080/15384047.2026.2760033
AB - Background: Although papillary thyroid carcinoma (PTC) has a relatively good prognosis, it is also prone to recurrence and metastasis. Cyclin-dependent kinase inhibitor 2 A (CDKN2A) can affect tumor progression by regulating ferroptosis, but its role in PTC remains unclear. Materials and methods: The expression of CDKN2A, p14, p16, GPX4, and TFRC in PTC was assessed by qPCR, western blotting, and immunohistochemistry, and their clinical correlations were analyzed. In TPC-1 and BCPAP cells, CDKN2A/p14/p16 expression was modulated, followed by evaluation of ferroptosis-related changes using GPX4, TFRC, Fe2⁺, ROS, GSH, C11-BODIPY lipid peroxidation, and transmission electron microscopy. Cell proliferation and migration were assessed by CCK-8, colony formation, wound-healing, and Transwell assays. The p53/SLC7A11/GPX4 pathway was examined, and rescue experiments were conducted using p53 agonist and inhibitor. In vivo tumorigenicity was evaluated using a nude mouse xenograft model. Results: CDKN2A was upregulated in PTC and associated with advanced clinicopathological features and lipid metabolism, but was not an independent prognostic factor. Silencing CDKN2A (p14, p16) induced ferroptosis, inhibiting tumor progression; in contrast, overexpression of p14 and p16 inhibited ferroptosis and promoted malignant phenotypes, with p16 playing a predominant role. Moreover, overexpression of p16 could partially resist the induction of ferroptosis by RSL3. Mechanistically, p53 agonist/inhibitor rescue experiments suggested p16 affected p53/SLC7A11/GPX4 pathway. In vivo, p16 overexpression increased tumor growth by inhibiting ferroptosis. Conclusion: CDKN2A promotes PTC progression by suppressing ferroptosis via indirect regulation of p53/SLC7A11/GPX4 pathway, primarily through the p16 isoform. Targeted inhibition of p16 isoform is a potential therapeutic strategy for PTC.
SN - 1538-4047
SN - 1555-8576
ER -